Close Menu

A consortium of researchers in the UK plans to sequence the whole genomes of 50 patients with osteosarcoma, and the whole-exomes of 100 additional samples, in an effort to develop personalized blood tests for patients and identify novel genes involved in the disease.

The research is being funded by the Skeletal Cancer Action Trust, and involves researchers and clinicians from the University College London Cancer Institute, the Royal National Orthopaedic Hospital, and the Wellcome Trust Sanger Institute.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.